CN115515979A - 与人IL-4Rα中特定表位结合的抗体及其应用 - Google Patents
与人IL-4Rα中特定表位结合的抗体及其应用 Download PDFInfo
- Publication number
- CN115515979A CN115515979A CN202180030276.2A CN202180030276A CN115515979A CN 115515979 A CN115515979 A CN 115515979A CN 202180030276 A CN202180030276 A CN 202180030276A CN 115515979 A CN115515979 A CN 115515979A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence shown
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 title claims abstract 31
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 title claims abstract 11
- 239000012634 fragment Substances 0.000 claims abstract 23
- 239000000427 antigen Substances 0.000 claims abstract 22
- 102000036639 antigens Human genes 0.000 claims abstract 22
- 108091007433 antigens Proteins 0.000 claims abstract 22
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 claims abstract 6
- 102000055229 human IL4 Human genes 0.000 claims abstract 6
- 238000012216 screening Methods 0.000 claims abstract 5
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims abstract 4
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract 4
- 230000019491 signal transduction Effects 0.000 claims abstract 4
- 239000011230 binding agent Substances 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 124
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 27
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 102000054663 human IL4R Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000004388 Interleukin-4 Human genes 0.000 claims 5
- 108090000978 Interleukin-4 Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940028885 interleukin-4 Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 241000282693 Cercopithecidae Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108090000176 Interleukin-13 Proteins 0.000 claims 3
- 241001529936 Murinae Species 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 102000019207 human interleukin-13 Human genes 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000000592 Nasal Polyps Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 238000002741 site-directed mutagenesis Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000001475 prostate lymphoma Diseases 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 abstract 2
- 239000002981 blocking agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5406—IL-4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
Abstract
本发明公开了一种人IL‑4R抗体或其抗原结合片段，该抗体或其抗原结合片段特异性结合人IL‑4Rα且与人IL‑4Rα中特定表位相结合。并且，本发明还提供所述表位在筛选人IL‑4R的结合剂或人IL‑4/IL‑13信号传导通路的阻断剂中的用途或者使用所述特定表位评价所述结合剂或阻断剂的药效中的用途。
Description
PCT国内申请，说明书已公开。
Claims (22)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020103316853 | 2020-04-24 | ||
| CN202010331685.3A CN113549151A (zh) | 2020-04-24 | 2020-04-24 | 与人IL-4Rα中特定表位结合的抗体及其应用 |
| PCT/CN2021/088139 WO2021213329A1 (zh) | 2020-04-24 | 2021-04-19 | 与人IL-4Rα中特定表位结合的抗体及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115515979A true CN115515979A (zh) | 2022-12-23 |
Family
ID=78101225
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010331685.3A Pending CN113549151A (zh) | 2020-04-24 | 2020-04-24 | 与人IL-4Rα中特定表位结合的抗体及其应用 |
| CN202180030276.2A Pending CN115515979A (zh) | 2020-04-24 | 2021-04-19 | 与人IL-4Rα中特定表位结合的抗体及其应用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010331685.3A Pending CN113549151A (zh) | 2020-04-24 | 2020-04-24 | 与人IL-4Rα中特定表位结合的抗体及其应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230167180A1 (zh) |
| EP (1) | EP4141031A4 (zh) |
| JP (1) | JP2023525665A (zh) |
| KR (1) | KR20230006837A (zh) |
| CN (2) | CN113549151A (zh) |
| AU (1) | AU2021258884A1 (zh) |
| TW (1) | TW202200621A (zh) |
| WO (1) | WO2021213329A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025026332A1 (zh) * | 2023-08-01 | 2025-02-06 | 先声药业有限公司 | 抗il4r抗体及其应用 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024539148A (ja) | 2021-10-20 | 2024-10-28 | サノフィ・バイオテクノロジー | Ｉｌ－４ｒアンタゴニストを投与することによって結節性痒疹を治療する方法 |
| KR20240135618A (ko) | 2021-12-30 | 2024-09-11 | 리제너론 파아마슈티컬스, 인크. | Il-4/il-13 길항제를 투여하여 아토피 행진을 약화시키는 방법 |
| WO2024011251A1 (en) | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
| WO2024047021A1 (en) | 2022-08-29 | 2024-03-07 | Sanofi | Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist |
| WO2024097714A1 (en) | 2022-11-01 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
| CN116041526B (zh) * | 2022-11-14 | 2023-09-29 | 华中农业大学 | 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用 |
| WO2024112935A1 (en) | 2022-11-23 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for improving bone growth by administering an il-4r antagonist |
| WO2024197119A1 (en) | 2023-03-22 | 2024-09-26 | Sanofi Biotechnology | Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist |
| WO2024206341A1 (en) | 2023-03-27 | 2024-10-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102197052A (zh) * | 2008-10-29 | 2011-09-21 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和性人抗体 |
| CN113166259A (zh) * | 2018-11-09 | 2021-07-23 | 亚洲大学校产学协力团 | 对人IL-4受体α具有高亲和力的人抗体及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2069403T3 (pl) * | 2006-10-02 | 2015-08-31 | Regeneron Pharma | Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4 |
| PL2245064T3 (pl) * | 2007-12-21 | 2015-01-30 | Medimmune Ltd | Elementy wiążące dla receptora alfa interleukiny-4 (IL-4ralfa) |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| WO2009121847A2 (en) * | 2008-04-02 | 2009-10-08 | Apogenix Gmbh | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| TWI784988B (zh) * | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| CN108373505B (zh) * | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
| CN111514292B (zh) * | 2018-12-25 | 2023-06-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
-
2020
- 2020-04-24 CN CN202010331685.3A patent/CN113549151A/zh active Pending
-
2021
- 2021-04-19 KR KR1020227039724A patent/KR20230006837A/ko unknown
- 2021-04-19 AU AU2021258884A patent/AU2021258884A1/en active Pending
- 2021-04-19 WO PCT/CN2021/088139 patent/WO2021213329A1/zh unknown
- 2021-04-19 US US17/997,025 patent/US20230167180A1/en active Pending
- 2021-04-19 EP EP21793385.2A patent/EP4141031A4/en active Pending
- 2021-04-19 JP JP2022564230A patent/JP2023525665A/ja active Pending
- 2021-04-19 CN CN202180030276.2A patent/CN115515979A/zh active Pending
- 2021-04-20 TW TW110114111A patent/TW202200621A/zh unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102197052A (zh) * | 2008-10-29 | 2011-09-21 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和性人抗体 |
| CN103739711A (zh) * | 2008-10-29 | 2014-04-23 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和性人抗体 |
| CN113166259A (zh) * | 2018-11-09 | 2021-07-23 | 亚洲大学校产学协力团 | 对人IL-4受体α具有高亲和力的人抗体及其用途 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025026332A1 (zh) * | 2023-08-01 | 2025-02-06 | 先声药业有限公司 | 抗il4r抗体及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021213329A1 (zh) | 2021-10-28 |
| EP4141031A1 (en) | 2023-03-01 |
| JP2023525665A (ja) | 2023-06-19 |
| CN113549151A (zh) | 2021-10-26 |
| TW202200621A (zh) | 2022-01-01 |
| EP4141031A4 (en) | 2024-04-24 |
| US20230167180A1 (en) | 2023-06-01 |
| AU2021258884A1 (en) | 2023-01-05 |
| KR20230006837A (ko) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115515979A (zh) | 与人IL-4Rα中特定表位结合的抗体及其应用 | |
| US11560429B2 (en) | Anti PD-1 antibodies | |
| Venkataramani et al. | Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies | |
| RU2008132968A (ru) | Антитела к рецептору тимусного стромального лимфопоэтина | |
| WO2011045704A1 (en) | Cancer treatment | |
| NZ748130A (en) | Humanized anti-il-1r3 antibodies | |
| HUE031923T2 (en) | Antibody molecules that exhibit binding specificity for human IL-13 | |
| AU2017258492A1 (en) | Interferon beta antibodies and uses thereof | |
| KR102571012B1 (ko) | 항-il-22r 항체 | |
| KR20250009424A (ko) | 항-tl1a 항체 및 그의 사용 방법 | |
| CN112480254A (zh) | 抗人白细胞介素-33受体的抗体及其制备方法和应用 | |
| WO2020102935A1 (en) | Anti-il-25 antibodies and use thereof | |
| EP2583979B1 (en) | Methods to prepare antibodies directed against p19 subunit of human IL-23 | |
| US11028178B2 (en) | Method of treating nonalcoholic steatohepatitis by administering an antagonist human tumor necrosis factor receptor 1 (HUTNFR1) antibody | |
| TW202402789A (zh) | 抗-tnfr2抗體及其使用方法 | |
| CN118871461A (zh) | 组合物 | |
| WO2021110873A1 (en) | Antibodies against lif and uses thereof | |
| EA044106B1 (ru) | АНТИ-huTNFR1 ТЕРАПИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА | |
| AU2014213579A1 (en) | Cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40086217 Country of ref document: HK |